Immunotherapy Vital to New Hematologic Cancer Approaches

November 24, 2018 matthewtaub14 Leave a comment

Immunotherapy pic — Immunotherapy
Image: webmd.com

Dr. Matthew Taub treats patients with cancer as an oncologist at Everglades Oncology and Hematology in Florida. Emphasizing evidence-based care, Dr. Matthew Taub also has extensive experience as a practicing hematologist focused on blood-related diseases.

As reported in the Oncology Times, one promising area of treatment involves the use of immunotherapy to address hematologic malignancies. One type of immunotherapy, allogeneic hematopoietic stem cell transplantation (HCT), has been employed for decades and has proved invaluable in treating leukemia in patients who undergo stem cell transplantation.

Immunological responses are a critical factor when undertaking HCT stem cell grafts, as the body often mounts immune responses against the transplants. Individualizing the immunotherapy approach with the help of big data enables the graft-versus-leukemia effect without triggering graft-versus-host disease.

Another advancement in immunotherapy involves CAR T-cell therapy, which has been FDA approved since 2017 and is effective in treating acute lymphoblastic leukemia. The new approach involves reprogramming healthy cells in ways that direct them to destroy cancer cells.

Health, Matthew Taub

The Role of Clinical Oncologists in Cancer Treatment

November 17, 2018 matthewtaub14 Leave a comment

Health, Matthew Taub

NCCN Global Initiatives Making Cancer Research Accessible

November 8, 2018 matthewtaub14 Leave a comment

National Comprehensive Cancer Network pic — National Comprehensive Cancer Network
Image: nccn.org

Board-certified oncologist Dr. Matthew Taub possesses more than two decades of experience administering care to patients with benign and malignant tumors. In his work as an oncology physician, Dr. Matthew Taub follows the industry-respected guidelines put forward by the National Comprehensive Cancer Network (NCCN) to evaluate treatment options for his patients.

To extend the impact of its research and initiatives, NCCN collaborates with cancer organizations around the world. In Africa, NCCN partners with the African Cancer Coalition to improve cancer patient outcomes in sub-Saharan Africa by expanding access to basic care. NCCN also has a strong presence in Asia and Europe, with more than 800,000 NCCN registered practitioners working on these continents.

To facilitate knowledge and resource sharing across its diverse membership base, NCCN translates its guidelines and content into several languages, including French, Korean, and Spanish. NCCN also adapts its guidelines to reflect regional differences in healthcare infrastructure, technology access, and genetic differences in populations.

Health, Matthew Taub

How Benign Tumors Differ from Malignant Tumors

October 19, 2018 matthewtaub14 Leave a comment

Dr. Matthew Taub, a physician with Optimum Oncology Hematology Associates, has been practicing medicine for more than 20 years. Throughout that time, Dr. Matthew Taub has treated both benign and malignant tumors.

Benign tumors are noncancerous growths that do not spread to other areas of the body. Although no specific cause of benign tumors is known, they have been linked to chronic inflammation, traumatic injury, and diet. Regardless, benign growths are common and can develop in any part of the body.

Though they are not cancerous, benign tumors can cause health problems, depending on their size and location. The growths may press against primary nerves or main arteries or compress brain matter. In these cases, the tumors will need to be treated or removed. Fortunately, benign tumors respond well to treatment and rarely grow back.

Infrequently, benign tumors can develop into malignant tumors. Because of this, benign tumors are typically monitored very closely, especially if they are classified as premalignant, which means the tumors have a high likelihood of becoming cancerous in the future.

Hematologist and Oncologist